BERN, Switzerland--(BUSINESS WIRE)--Not for US or UK media Data published online in the current edition of Journal of Clinical Immunology demonstrates that Privigen™, the new liquid immune globulin intravenous (human) 10 percent product from CSL Behring, is effective and well-tolerated in patients with Primary Immune Deficiencies (PI). PI is a group of predominantly genetic disorders that cause a malfunction in part or all of the immune system, leaving patients susceptible to potentially life-threatening infections.
